MedPath

PET/MRI Perfusion and CT Perfusion in Solid Tumors

Terminated
Conditions
CT Perfusion and MRI Perfusion in Solid Tumors
Registration Number
NCT02314962
Lead Sponsor
University of Zurich
Brief Summary

Diagnostic comparison between PET/CT and PET/MRI with integrated perfusion measurement in CT and MR. Study aim is to gain knowledge about additional value of CT perfusion and MR perfusion in solid tumors concerning tumor physiology, diagnostic accuracy and possibly prognostic.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
43
Inclusion Criteria
  • indication as stated above
  • written informed consent
  • patients with suspected or confirmed solid malignant tumors of the neck, chest or abdomen who have an indication for a PET/CT
Read More
Exclusion Criteria
  • pregnant or breast feeding women
  • non compliance of the patient to follow the study instructions (e.g. hearing problems, dementia)
  • Inclusion in another clinical trial 30 days prior to inclusion
  • age < 30years
  • contraindication for MRI (cardiac pacemaker, certain metal implants, claustrophobia
  • known allergies to contrast CT or MRI contrast media
  • patients with an glomerular filtration rate of < 60ml/min/1.73m2
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Measurement of blood flow, blood volume and transfer constant (Ktrans) with CT-Perfusion and PET/MR-perfusion in solid tumors.18 months
Secondary Outcome Measures
NameTimeMethod
Correlation of blood flow, blood volume and transfer constant (Ktrans) measured with CT-Perfusion and PET/MR-perfusion with progression free survival in solid tumors.18 months

Trial Locations

Locations (1)

University Hospital Zurich, Diagnostic and Interventional Radiology

🇨🇭

Zurich, ZH, Switzerland

© Copyright 2025. All Rights Reserved by MedPath